Do you want to read an article? Please log in or register.
Effects of nintedanib by inclusion criteria for progression of interstitial lung disease
Interstitial Lung DiseasePulmonary FibrosisPneumonia
RECOMMENDED
Related content
RECOMMENDED
Interstitial Lung DiseasePulmonary Fibrosis
Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial
★ 3
Recommended by
Dr Martin Frey, Faculty Member
★ 3
Recommended by
Dr Marcus Hesse, Faculty Member
Lancet Respir Med.
Wells AU, Flaherty KR, Brown KK, Inoue Y, Devaraj A, Richeldi L, Moua T, Crestani B, Wuyts WA, Stowasser S, Quaresma M, Goeldner RG, Schlenker-Herceg R, Kolb M, INBUILD trial investigators.
doi: 10.1016/S2213-2600(20)30036-9.
RECOMMENDED
Interstitial Lung DiseasePulmonary Fibrosis
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
★ 3
Recommended by
Dr Martin Frey, Faculty Member
★ 3
Recommended by
Dr Marcus Hesse, Faculty Member
N Engl J Med.
Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, Richeldi L, Kolb M, Tetzlaff K, Stowasser S, Coeck C, Clerisme-Beaty E, Rosenstock B, Quaresma M, Haeufel T, Goeldner RG, Schlenker-Herceg R, Brown KK, INBUILD Trial Investigators.
doi: 10.1056/NEJMoa1908681.
Interstitial Lung Disease
Telomere Length and Genetic Variant Associations with Interstitial Lung Disease Progression and Survival
Eur Respir J.
Newton CA, Oldham JM, Ley B, Anand V, Adegunsoye A, Liu G, Batra K, Torrealba J, Kozlitina J, Glazer C, Strek ME5, Wolters PJ, Noth I, Garcia CK
doi: 10.1183/13993003.
RECOMMENDED
Interstitial Lung DiseasePulmonary Fibrosis
Fibrotic interstitial lung diseases and air pollution: a systematic literature review
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Eur Respir Rev.
Harari S, Raghu G, Caminati A, Cruciani M, Franchini M, Mannucci P
doi: 10.1183/16000617.0093-2020.
RECOMMENDED
Interstitial Lung DiseasePulmonary Fibrosis
Potential of Nintedanib in Treatment of Progressive Fibrosing Interstitial Lung Diseases
Eur Respir J.
Wollin L, Distler JHW, Redente EF, Riches DWH, Stowasser S, Schlenker-Herceg R, Maher TM, Kolb M
doi: 10.1183/13993003.00161-2019.
RECOMMENDED
Interstitial Lung Disease
Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease
N Engl J Med.
Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, Raghu G, Sauter W, Girard M, Alves M, Clerisme-Beaty E, Stowasser S, Tetzlaff K, Kuwana M, Maher TM, SENSCIS Trial Investigators.
doi: 10.1056/NEJMoa1903076.
RECOMMENDED
Interstitial Lung Disease
Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 3
Recommended by
Dr Marcus Hesse, Faculty Member
Eur Respir J
Flaherty KR, Wells AU, Cottin V, Devaraj A, Inoue Y, Richeldi L, Walsh SLF, Kolb M, Koschel D, Moua T, Stowasser S, Goeldner RG, Schlenker-Herceg R, Brown KK, INBUILD trial investigators.
doi: 10.1183/13993003.04538-2020
RECOMMENDED
Interstitial Lung Disease
The psychometric properties of the King's Brief Interstitial Lung Disease questionnaire and thresholds for meaningful treatment response in patients with progressive fibrosing interstitial lung diseases
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Eur Respir J
Birring SS, Bushnell DM, Baldwin M, Mueller H, Male N, Rohr KB, Inoue Y
doi: 10.1183/13993003.01790-2021
RECOMMENDED
Interstitial Lung Disease
Predicting outcomes in rheumatoid arthritis related interstitial lung disease
Eur Respir J.
Jacob J, Hirani N, van Moorsel CHM, Rajagopalan S, Murchison JT, van Es HW, Bartholmai BJ, van Beek FT, Struik MHL, Stewart GA, Kokosi M, Egashira R, Brun AL, Cross G, Barnett J, Devaraj A, Margaritopoulos G, Karwoski R, Renzoni E, Maher TM, Wells AU
doi: 10.1183/13993003.00869-2018.